Latest Conference Articles

October 14th 2018, 9:08pm

Lynn Sage Breast Cancer Symposium

William J. Gradishar, MD, discusses how far the breast cancer field has advanced over the last 20 years and the data he is anticipating to read out in the future.

October 14th 2018, 9:00pm

Lynn Sage Breast Cancer Symposium

Multiple gene signature assays have been developed that supply prognostic information for decisions on adjuvant chemotherapy and whether therapy should be of extended duration.

October 14th 2018, 1:00am

Lynn Sage Breast Cancer Symposium

Determining the optimal adjuvant therapy in young women with breast cancer remains challenging, but some clarity is beginning to emerge.

October 13th 2018, 7:35pm

Lynn Sage Breast Cancer Symposium

Kathryn Ruddy, MD, discusses how genetic testing could impact treatment of patients with breast cancer.

October 13th 2018, 5:17pm

Lynn Sage Breast Cancer Symposium

Andrea V. Barrio, MD, discusses the challenges with phyllodes tumors of the breast and how to manage this disease moving forward.

October 13th 2018, 5:13pm

Lynn Sage Breast Cancer Symposium

Elizabeth Mittendorf, MD, PhD, discusses the rationale for updating the AJCC staging system in patients with breast cancer. This system was originally developed in the 1970s but is still used today.

October 13th 2018, 4:27pm

Lynn Sage Breast Cancer Symposium

All triple-negative breast cancers are not created equal, and clinicians should consider their inherent heterogeneity during diagnosis and treatment planning.

October 13th 2018, 12:25am

Lynn Sage Breast Cancer Symposium

Monica Morrow, MD, addresses how she treats patients with breast cancer who have locoregional recurrence and how therapeutic approaches have evolved over recent years.

October 12th 2018, 9:21pm

Lynn Sage Breast Cancer Symposium

Sara McLaughlin, MD, professor of Surgery, Mayo Clinic, discusses the frequency that lymphedema appears in patients with breast cancer and addresses the complications in identifying this after her presentation at the Lynn Sage Breast Cancer Symposium.

October 12th 2018, 8:32pm

State of the Science Summit on GI Malignancies

Afsaneh Barzi, MD, assistant professor of clinical medicine, USC Norris Comprehensive Cancer Center, discusses surgical advances in the treatment of patients with pancreatic cancer.

October 12th 2018, 7:38pm

Lynn Sage Breast Cancer Symposium

Just as immunotherapies are transforming clinical practice for oncologists, these new therapies are also changing the practice of pathology and offering new ways for oncologists and pathologists to collaborate and improve patient care.

October 12th 2018, 6:15pm

Lynn Sage Breast Cancer Symposium

Luis Z. Blanco Jr., MD, assistant professor of Pathology, Northwestern University, discusses the role a pathologist plays in the treatment of a patient with breast cancer during a presentation at the Lynn Sage Breast Cancer Symposium.

October 12th 2018, 1:27am

Lynn Sage Breast Cancer Symposium

Scalp cooling to limit alopecia in patients with cancer who are receiving chemotherapy is edging closer to becoming a widespread patient offering following recent FDA clearances.

October 11th 2018, 12:09am

State of the Science Summit on Hematologic Malignancies

Jason Valent, MD, oncologist, Cleveland Clinic, discusses the potential application of minimal residual disease (MRD) negativity in patients with multiple myeloma.

October 11th 2018, 12:09am

State of the Science Summit on Hematologic Malignancies

Hetty Carraway, MD, oncologist, Cleveland Clinic, discusses predisposition to acute myeloid leukemia (AML).

October 11th 2018, 12:07am

State of the Science Summit on Hematologic Malignancies

Aaron Gerds, MD, discusses the activity and drawbacks with current systemic agents in myeloproliferative neoplasms.

October 11th 2018, 12:06am

State of the Science Summit on Hematologic Malignancies

Mikkael A. Sekeres, MD, discusses the characteristics of myelodysplastic syndrome and the evolving armamentarium of treatment.

October 10th 2018, 11:56pm

State of the Science Summit on Hematologic Malignancies

Jeffrey A. Zonder, MD, discusses triplet regimens in multiple myeloma and patient eligibility for clinical trials.

September 29th 2018, 1:10am

Lynn Sage Breast Cancer Symposium

Advances in subtype-specific treatments, immunotherapy, ongoing issues with younger patients, the optimal use of neoadjuvant and adjuvant regimens, and molecular testing will be discussed at the 20th Annual Lynn Sage Breast Cancer Symposium.

September 17th 2018, 12:59am

International Liver Cancer Association Annual Conference

The development of novel immunotherapy combinations is among the most significant trends emerging as part of the next wave of discovery in hepatocellular carcinoma, with several promising regimens incorporating checkpoint inhibitors undergoing testing in phase III studies.